

# EP26

## User Evaluation of Acceptability of a Reagent Lot Change

This guideline includes recommendations for laboratories on evaluating a new reagent lot, based on a protocol that uses patient samples to detect clinically important changes from the current lot.

.....

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

---

## User Evaluation of Acceptability of a Reagent Lot Change

Jesper V. Johansen, PhD  
Lorin M. Bachmann, PhD, DABCC, MT(ASCP)  
Nikolina Babic, PhD, DABCC  
Paul Michael D'Agostino, PhD  
Uliana Danilenko, PhD  
A. Paul Durham, MA  
Marc D. Goldford, BS

Isolde Seiden Long, PhD, DCC, FCACB, DABCC  
W. Gregory Miller, PhD  
Nils B. Person, PhD, FAACC  
Johnathan Eric Stanford, MHA, MLS(ASCP)<sup>CM</sup>  
Nico Vandepoele  
Anca Roxana Varlan, PhD

### Abstract

---

Clinical and Laboratory Standards Institute guideline EP26—*User Evaluation of Acceptability of a Reagent Lot Change* provides recommendations for laboratories on evaluating a new reagent lot, based on a protocol that uses patient samples to detect clinically important changes from the current lot. It provides guidance on determining whether lot-to-lot differences are significant and whether an observed difference is acceptable based on the established criteria. The protocol attempts to balance the need to detect changes in reagent performance that may adversely affect patient results with the fact that reagent lot verification is a relatively frequent task that places demands on the laboratory's limited resources. The more extensive initial setup of the protocol at the individual site is a one-time task performed in advance, making the subsequent testing of new reagent lots a straightforward procedure.

Clinical and Laboratory Standards Institute (CLSI). *User Evaluation of Acceptability of a Reagent Lot Change*. 2nd ed. CLSI guideline EP26 (ISBN 978-1-68440-137-6 [Print]; ISBN 978-1-68440-138-3 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2022.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@cls.org](mailto:customerservice@cls.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2022 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *User Evaluation of Acceptability of a Reagent Lot Change*. 2nd ed. CLSI guideline EP26. Clinical and Laboratory Standards Institute; 2022.

**Previous Edition:**

September 2013

EP26-Ed2

ISBN 978-1-68440-137-6 (Print)

ISBN 978-1-68440-138-3 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 42, Number 11

.....

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council>

### Document Development Committee on Between-Reagent Lot Variation

**Jesper V. Johansen, PhD**  
Chairholder  
Radiometer Medical ApS  
Denmark

Uliana Danilenko, PhD  
Centers for Disease Control and  
Prevention  
USA

Nico Vandepoele  
Bio-Rad Laboratories, Inc.  
USA

**Lorin M. Bachmann, PhD, DABCC,  
MT(ASCP)**  
Vice-Chairholder  
Virginia Commonwealth University  
Health System  
USA

Marc D. Goldford, BS  
Sekisui Diagnostic LLC  
USA

Anca Roxana Varlan, PhD  
Epocal, A Siemens Healthineers  
Company  
Canada

Nikolina Babic, PhD, DABCC  
AACC  
USA

Isolde Seiden Long, PhD, DCC, FCACB,  
DABCC  
Alberta Precision Laboratories  
Canada

Paul Michael D'Agostino, PhD  
Siemens Healthineers  
USA

Johnathan Eric Stanford, MHA,  
MLS(ASCP)<sup>CM</sup>  
Vanderbilt University Medical Center  
USA

### Expert Panel on Evaluation Protocols

Expert Panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert Panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Laura Martin  
*Editorial Manager*

Kristy L. Leirer, MS  
*Editor*

Tabitha Kern, MS, MLS(ASCP)<sup>CM</sup>  
*Project Manager*

Catherine E.M. Jenkins, ELS  
*Editor*

## Acknowledgment

---

CLSI, the Consensus Council, and the Document Development Committee on Between-Reagent Lot Variation gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

A. Paul Durham, MA  
APD Consulting  
USA

W. Gregory Miller, PhD  
Virginia Commonwealth  
University  
USA

Nils B. Person, PhD, FAACC  
USA

# Contents

Abstract	i
Committee Membership	iii
Foreword	vii
<b>Chapter 1: Introduction</b>	<b>1</b>
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	4
<b>Chapter 2: Path of Workflow</b>	<b>9</b>
2.1 Stage 1: Determining Protocol Parameters	13
2.2 Stage 2: Evaluating Candidate Reagent Lots	14
2.3 Defining When Lot-to-Lot Verification Should Be Performed	14
<b>Chapter 3: Establishing Key Parameters</b>	<b>15</b>
3.1 Determining Critical Difference for a Lot-to-Lot Comparison	16
3.2 Defining the Rejection Limit for a Lot-to-Lot Comparison	21
3.3 Determining the Concentration(s) at Which to Evaluate Lot-to-Lot Difference	26
<b>Chapter 4: Selecting Samples for Reagent Lot Comparability Testing</b>	<b>27</b>
4.1 Patient Samples	28
4.2 Pooled Patient Samples	30
4.3 Reference and Quality Control Materials	30
<b>Chapter 5: Evaluating Lot-to-Lot Differences</b>	<b>33</b>
5.1 Stage 1: Planning Reagent Lot-to-Lot Difference Testing	34
5.2 Stage 2: Evaluating Lot-to-Lot Differences	38
5.3 Investigating Between-Lot Differences in Patient Sample or Quality Control Results	39
<b>Chapter 6: Limitations to the Protocol</b>	<b>41</b>
6.1 Potential Sources of Systematic Differences	42
6.2 Equivalence Tests Across Multiple Instruments and Sites	42
6.3 Problems With Using Reagent Lot Equivalence Testing to Monitor Long-Term Trends	43
<b>Chapter 7: Examples of Evaluating Between-Lot Shifts Using Patient Data</b>	<b>45</b>
7.1 Stage 1: Setup	46
7.2 Stage 2: Lot Evaluation	54

# Contents (Continued)

.....

Chapter 8: Conclusion ..... 57

Chapter 9: Supplemental Information ..... 59

    References ..... 60

**Appendix A.** Tables to Determine the Number of Samples Needed and the Rejection Limit ..... 65

**Appendix B.** Statistical Considerations for Determining the Number of Samples ..... 77

**Appendix C.** Determining Within–Reagent Lot Imprecision and Repeatability–to–Within–Reagent Lot  
 Imprecision Ratios Using Precision Profiles ..... 91

**Appendix D.** Determining Within–Reagent Lot Imprecision and Repeatability–to–Within–Reagent Lot  
 Imprecision Ratios From Multiple Precision Sources ..... 101

**Appendix E.** Estimating the False Rejection Rate on Retest ..... 105

**The Quality Management System Approach** ..... 110

## Foreword

A change in reagent lot may lead to changes in measurement procedure performance. Possible causes of this phenomenon include changes in reagent component materials, instability of a component in a reagent, damage during transportation or storage, or incorrect calibration of the new reagent lot. Consequently, it is good laboratory practice to verify the consistency of patient sample results when a new reagent lot is introduced.

Historically, testing of QC samples has often been used as a primary tool to verify new reagent lot performance. However, although testing QC samples is key to monitoring measurement procedure performance over time, it may not be a reliable indicator of lot-to-lot consistency for all measurement procedures. A new reagent lot may lead to a shift in the results obtained with QC samples. These changes in QC results are often caused by a difference in the interaction of the QC material with the current vs new reagent lots, commonly referred to as a matrix effect, although there is no change in the measurement procedure performance as measured with patient sample results. It is also possible for a reagent lot–related change in measurement procedure performance to affect patient sample results with little or no apparent effect on QC sample results. In such instances, an insignificant change in QC results from one reagent lot to the next could mask a significant change in patient sample results.

This guideline describes a systematic approach for detecting significant changes in measurement procedure performance for patient samples due to reagent lot changes and for confirming that patient sample results are consistent between two reagent lots.

### Overview of Changes

This guideline replaces the previous edition of the approved guideline, EP26-A, published in 2013. Several changes were made in this edition, including:

- More clearly delineating the two stages of the protocol to clarify that the setup stage is performed only once, before any new reagent lot evaluations
- Providing additional detail about the statistical techniques used, so that the included tables can be extended as needed
- Revising discussion of allowable total analytical error (TEa) as a basis for determining critical difference (CD) to align with current recommendations and to improve clarity regarding the relationship between the CD and TEa
- Expanding the examples of reagent lot change evaluation to provide more detail on determining the CD and other critical parameters

This guideline describes a practical approach for screening new reagent lots for clinically significant performance changes with patient samples. This protocol is designed to use a small number of samples. Thus, lots can be screened quickly with limited resources. The protocol consists of two stages:

- **Stage 1** sets up the protocol for each analyte. This stage involves making decisions about the medically acceptable differences caused by reagent lot change and the acceptable risks associated with incorrect inferences. However, this stage can be performed before any reagent lots are evaluated.
- **Stage 2** is the evaluation of a new reagent lot, using the protocol developed in stage 1. This stage is simple and rapid and is performed for every new reagent lot.

Additionally, the process described enables the laboratory to determine the effectiveness of the protocol used, including the expected probability of detecting a significant lot-to-lot difference and the probability of falsely rejecting an acceptable lot. The process also shows how factors such as measurement procedure imprecision and choice of CD affect the effectiveness and practicality of the chosen protocol. No single fixed protocol is appropriate for all measurement procedures. Therefore, this guideline provides recommendations on developing specific protocols.

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

**KEY WORDS****Commutability****Matrix effect****Quality control****Critical difference****Matrix-related bias****Reagent lot**

# Chapter ①

## Introduction

# User Evaluation of Acceptability of a Reagent Lot Change

## 1 Introduction

### 1.1 Scope

This guideline describes a statistically sound protocol for evaluating the consistency of patient sample results when a new analytical reagent lot replaces a reagent lot currently in use. It is designed for use with quantitative measurement procedures, and more generally for measurement procedures that report on a continuous scale. The same principles can be applied to measurement procedures that convert results from a continuous scale to a qualitative report based on a cutoff value. This guideline is intended for use in the medical laboratory and is designed to work within the practical limitations of that environment.

This guideline is not intended for use with measurement procedures that provide only qualitative or semiquantitative results. It is also not intended for measurement procedures for which a shift in patient results is expected with new reagent lots. For some measurement procedures, a shift in patient results with a new reagent lot is usual and expected, because the reagents are biological materials that may have lot-to-lot differences. Such measurement procedures include prothrombin time and activated partial thromboplastin time. The usual processes for clinical use of these measurement procedures account for this expected difference, and new lot evaluation as described in this guideline is not necessary or useful. Guidance for these measurement procedures provides detail on handling reagent lot changes. See CLSI documents H47<sup>1</sup> and H54.<sup>2</sup>

Additionally, this guideline is not intended to describe procedures for reagent manufacturers. The requirements of reagent lot-to-lot testing by manufacturers, as well as the resources available, are different from those of the medical laboratory. However, reagent manufacturers may use this guideline to understand the types of verification studies that may be performed in their customers' laboratories.

### 1.2 Background

The potential for a change in performance with a new reagent lot has been shown for both QC and patient samples. This possibility is recognized by regulatory and accreditation organizations, which have incorporated verification of the performance of a new reagent lot into their recommendations for good laboratory practice.<sup>3-11</sup>

The goal of both reagent manufacturers and medical laboratories is to provide accurate patient results. Reagent manufacturers use several procedures to validate the performance of a new reagent lot during the manufacturing process. Reagents are available to medical laboratories only when the performance criteria are met. As part of the overall quality process, manufacturers may compile information on the expected lot-to-lot consistency of patient sample results, as established internally or at other laboratories. However, because of differences in the study designs used, the manufacturer's protocols and acceptance criteria for lot-to-lot variability may not be applicable for medical laboratories. Specific acceptability limits apply only to the associated protocol for which the limits were developed. Therefore, this guideline focuses on establishing a critical difference (CD), which is based on an acceptability limit defined by the laboratory according to the measurement procedure's clinical use.